Compare KO & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KO | AMGN |
|---|---|---|
| Founded | 1886 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.0B | 251.6B |
| IPO Year | 2004 | 2002 |
| Metric | KO | AMGN |
|---|---|---|
| Price | $97.54 | $468.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 34 |
| Target Price | $98.43 | ★ $431.81 |
| AVG Volume (30 Days) | ★ 15.5M | 2.5M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.17% | 2.15% |
| EPS Growth | 23.58 | ★ 88.23 |
| EPS | 2.86 | ★ 14.79 |
| Revenue | ★ $47,941,000,000.00 | $25,424,000,000.00 |
| Revenue This Year | $5.23 | $7.41 |
| Revenue Next Year | N/A | $4.59 |
| P/E Ratio | $34.15 | ★ $31.64 |
| Revenue Growth | 1.87 | ★ 8.83 |
| 52 Week Low | $67.27 | $312.39 |
| 52 Week High | $97.73 | $483.99 |
| Indicator | KO | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.05 | 64.01 |
| Support Level | $85.32 | $326.58 |
| Resistance Level | N/A | $483.99 |
| Average True Range (ATR) | 1.67 | 11.96 |
| MACD | 0.22 | -0.26 |
| Stochastic Oscillator | 91.73 | 64.68 |
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around 60% of its total revenue overseas, with sizable contributions from emerging economies in Latin America and Asia-Pacific.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.